In this episode, researchers explore how asymptomatic versus symptomatic hypertension affects heart failure patients on sacubitril valsartan, finding that both types are linked to worse outcomes, but the drug’s benefits remain strong, suggesting clinicians should avoid stopping treatment based solely on blood pressure.